feel bad for folks who are buying. This is the guy that killed biotech he charged $700 for a $13 pill
Clovis Oncology, Inc. - Ir
The following excerpt is from the company's SEC filing.
As the efficacy data had matured, the number of patients with an unconfirmed response who converted to a confirmed response was lower than expected. In the intent-to-treat analysis of the 79 patients in the 500 milligrams dose group, the current confirmed response rate is 28% and in the 170 patients in the 625
milligram dose group, its 34%. In both cases we have a duration of response of nine months.
Belbuca will provide a novel, alternative treatment option for millions of people suffering with chronic pain. Clinical trials demonstrated that twice daily administration of Belbuca was well tolerated and controlled moderate to severe chronic pain. Belbuca will also provide healthcare practitioners and their patients with a new buprenorphine treatment option. Buprenorphine is a Schedule III controlled substance, meaning that it has been defined as having lower abuse potential than Schedule II drugs, a category that includes most opioid analgesics.
FDA Approval Changes the Game for BioDelivery Scienc (NASDAQ: BDSI)
Belbuca will provide a novel, alternative treatment option for millions of people suffering with chronic pain. Clinical trials demonstrated that twice daily administration of Belbuca was well tolerated and controlled moderate to severe chronic pain.
3 Day Rule
grabbed a bunch today.
Sentiment: Strong Buy
Esperion Plunges on FDA Advice for Cardiovascular Study
However, investors seem to be disappointed by the FDA's request for a cardiovascular outcomes study, which is to be conducted at the earliest.
We believe that the FDA's advice has a serious implication regarding the timing of NDA submission for ETC-1002. Launch of a new study will involve a lot of resources and could take a long time (even years) tocomplete. Hence, it will substantially delay the submission of an NDA for ETC-1002. If approved, the drug may face a challenge in gaining market share due to late entry into the market